Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sensus Drug Development Corp.

Division of Pfizer Inc.

Latest From Sensus Drug Development Corp.

Engineering Protein Pharmaceuticals

Sophisticated protein engineering has largely been the domain of major biopharmaceutical companies. But genomics is flooding researchers with new proteins of unknown function and traditional techniques for turning them into drugs or for understanding their potential as drug targets are generally too slow. Start-ups around phage display, protein evolution, and synthetic protein chemistries are offering what look like faster, cheaper alternatives. But the size of the partnership opportunity for these new companies is uncertain, since drug companies still appear reluctant to embark on the development of protein drugs. In response, the start-ups are also trying to exploit the technologies for small-molecule drug discovery.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • John A Scarlett, MD, Pres. & CEO
    William F Bennett, PhD, SVP, Research & CSO
    Robert J Davis, PharmD, EVP
    Precht Magnus, SVP, Sales & Mktg.
  • Contact Info
  • Sensus Drug Development Corp.
    Phone: (512) 476-0270
    98 San Jacinto Blvd.
    Austin, TX 78701